ID: ALA4554146

Max Phase: Preclinical

Molecular Formula: C22H24F2N4O3

Molecular Weight: 430.46

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=C1N(CCO)c2cc(F)cc(F)c2C12CCN(c1nc3c(c(=O)[nH]1)CCCC3)CC2

Standard InChI:  InChI=1S/C22H24F2N4O3/c23-13-11-15(24)18-17(12-13)28(9-10-29)20(31)22(18)5-7-27(8-6-22)21-25-16-4-2-1-3-14(16)19(30)26-21/h11-12,29H,1-10H2,(H,25,26,30)

Standard InChI Key:  PQGLPXUXVBAMGX-UHFFFAOYSA-N

Associated Targets(Human)

Tankyrase-1 1241 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tankyrase-2 1531 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tankyrase 1/2 384 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

COLO 320DM 191 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Poly [ADP-ribose] polymerase-1 6206 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RKO 1376 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 430.46Molecular Weight (Monoisotopic): 430.1816AlogP: 1.80#Rotatable Bonds: 3
Polar Surface Area: 89.53Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.21CX Basic pKa: 3.20CX LogP: 1.54CX LogD: 1.48
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.78Np Likeness Score: -1.08

References

1. Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H..  (2020)  Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.,  63  (8): [PMID:32202790] [10.1021/acs.jmedchem.0c00045]
2. Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H..  (2019)  Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.,  62  (7): [PMID:30883102] [10.1021/acs.jmedchem.8b01888]

Source